Micromet Announces Presentations on BiTE Antibody Programs at AACR Annual Meeting
BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.
Presentation details: |
|
Poster Title: "Validation of Cynomolgus monkeys as relevant species for safety |
|
assessment of a novel human BiTE antibody platform for cancer therapy" |
|
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET |
|
Presenter: Benno Rattel, Micromet |
|
Abstract Number: 2435 |
|
Location: Exhibit Hall A – C, Poster Session 18 |
|
Poster Title: "Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on |
|
monoclonal antibody cetuximab (Erbitux)" |
|
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET |
|
Presenter: Ralf Lutterbuese, Micromet |
|
Abstract Number: 2429 |
|
Location: Exhibit Hall A – C, Poster Session 18 |
|
Poster Title: "Novel primate-crossreactive BiTE antibodies that eliminate cancer cells expressing |
|
cMet, IGFR-1, FAP-alpha, PSCA, endosialin, CAIX or Her2/neu" |
|
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET |
|
Presenter: Tobias Raum, Micromet |
|
Abstract Number: 2434 |
|
Location: Exhibit Hall A – C, Poster Session 18 |
|
Poster Title: "Eradication of established pancreatic tumors in mice by engagement of extra-tumoral |
|
human T cells with BiTE antibody MT110" |
|
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET |
|
Presenter: Matthias Friedrich, Micromet |
|
Abstract Number: 2433 |
|
Location: Exhibit Hall A – C, Poster Session 18 |
|
Poster Title: "The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a |
|
nonlinear epitope present in the full-length but not a short splice variant of CEA" |
|
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET |
|
Presenter: Li Peng, MedImmune |
|
Abstract Number: 2584 |
|
Location: Exhibit Hall A – C, Poster Session 24 |
|
Poster Title: "Inhibition of breast cancer cell proliferation and unique epitope |
|
recognition by EpCAM-specific human monoclonal antibody adecatumumab" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Markus Muenz, Micromet |
|
Abstract Number: 5339 |
|
Location: Exhibit Hall A – C, Poster Session 19 |
|
Poster Title: "Impact of binding epitope and antigen size on the cytotoxic activity of MCSP-specific BiTE antibodies for treatment of melanoma" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Claudia Bluemel, Micromet |
|
Abstract Number: 5340 |
|
Location: Exhibit Hall A – C, Poster Session 19 |
|
Poster Title: "Metastatic colorectal cancer cells from patients previously treated with chemotherapy |
|
are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Takuya Osada, Duke University |
|
Abstract Number: 5338 |
|
Location: Exhibit Hall A – C, Poster Session 19 |
|
Poster Title: "MCSP/CD3 bispecific single-chain antibody construct engages CD4+ |
|
and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Jacobus Bosch, Erlangen University |
|
Abstract Number: 5621 |
|
Location: Exhibit Hall A – C, Poster Session 31 |
|
Poster Title: "In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel |
|
CEA/CD3-bispecific single-chain BiTE antibody for the treatment of gastrointestinal |
|
adenocarcinomas" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Stacey Fuhrmann, MedImmune, LLC |
|
Abstract Number: 5625 |
|
Location: Exhibit Hall A – C, Poster Session 31 |
|
Poster Title: "Single-chain bispecific BiTE antibody specific for CD3 and |
|
melanoma-associated chondroitin sulfate proteoglycan: In vitro and in vivo anti-melanoma activity" |
|
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET |
|
Presenter: Hans Schoellhammer, John Wayne Cancer Center |
|
Abstract Number: 5626 |
|
Location: Exhibit Hall A – C, Poster Session 31 |
|
Abstracts can be accessed through the AACR website, www.aacr.org. All posters will be accessible from Micromet's website at www.micromet-inc.com after they are presented.
About BiTE Antibodies
BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
About Micromet
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com
SOURCE Micromet, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article